We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES.
- Authors
Cheson, B. D.; Morschhauser, F.; Assouline, S. E.; Michallet, A.; Tani, M.; Paris, G.; Sun, W.; Atwal, S. K.; Hong, W.; Sarkozy, C.
- Abstract
Aggressive B-cell lymphoma subtypes, including diffuse large B-cell lymphoma not otherwise specified, gray zone lymphoma, follicular lymphoma grade 3b, high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma or large B-cell lymphoma transformed from indolent B-cell, are eligible to enroll. B Introduction: b PRT2527 is a potent, highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B-CELL MALIGNANCIES.
- Subjects
DIFFUSE large B-cell lymphomas; MANTLE cell lymphoma
- Publication
Hematological Oncology, 2023, Vol 41, p829
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3166_OT11